FIC20220003I1 - Vosoritidi - Google Patents

Vosoritidi

Info

Publication number: FIC20220003I1
Authority: FI; Finland
Prior art keywords: vosoritide
Prior art date: 2009-05-20

Application number

FIC20220003C

Other languages

English (en)

Original Assignee

Biomarin Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-20

Filing date

2022-01-19

Publication date

2022-01-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43124672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FIC20220003(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2022-01-19 Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc

2022-01-19 Publication of FIC20220003I1 publication Critical patent/FIC20220003I1/fi

Links

IGYWDDBBJPSOTG-WBAGYEQSSA-N vosoritide Chemical compound CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](Cc5cnc[nH]5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@@H]6CCCN6 IGYWDDBBJPSOTG-WBAGYEQSSA-N 0.000 title 1
229950010005 vosoritide Drugs 0.000 title 1
108700022781 vosoritide Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Diabetes (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

FIC20220003C 2009-05-20 2022-01-19 Vosoritidi FIC20220003I1 (fi)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US18011209P	2009-05-20	2009-05-20
US25456309P	2009-10-23	2009-10-23

Publications (1)

Publication Number	Publication Date
FIC20220003I1 true FIC20220003I1 (fi)	2022-01-19

Family

ID=43124672

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FIC20220003C FIC20220003I1 (fi)	2009-05-20	2022-01-19	Vosoritidi

Country Status (27)

Country	Link
US (6)	US8198242B2 (fi)
EP (5)	EP3175863B1 (fi)
JP (1)	JP5718909B2 (fi)
KR (5)	KR102033680B1 (fi)
CN (1)	CN102481330B (fi)
AR (1)	AR078044A1 (fi)
AU (1)	AU2010249802B2 (fi)
BR (2)	BR122019026832B1 (fi)
CA (1)	CA2758581C (fi)
CL (1)	CL2011002430A1 (fi)
DK (2)	DK2432489T3 (fi)
ES (2)	ES2608457T3 (fi)
FI (1)	FIC20220003I1 (fi)
FR (1)	FR22C1004I2 (fi)
HR (2)	HRP20161739T1 (fi)
HU (3)	HUE032582T2 (fi)
IL (1)	IL215287A (fi)
LU (1)	LUC00248I2 (fi)
MX (1)	MX2011012277A (fi)
NO (1)	NO2022003I1 (fi)
PE (1)	PE20120792A1 (fi)
PL (2)	PL2432489T3 (fi)
PT (2)	PT3175863T (fi)
RU (1)	RU2573911C2 (fi)
TW (1)	TWI471137B (fi)
WO (1)	WO2010135541A2 (fi)
ZA (1)	ZA201107087B (fi)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1759001T3 (da)	2004-04-21	2011-08-01	Enobia Pharma Inc	Konjugat til tilførsel til knogler og fremgangsmåde til fremstilling deraf ved at målrette proteiner til knoglen
PT3175863T (pt)	2009-05-20	2022-01-20	Biomarin Pharm Inc	Variantes do péptido natriurético de tipo c
CN102470163B (zh)	2009-07-23	2016-06-15	Igisu株式会社	皮肤外用剂组合物
JP4790096B2 (ja)	2009-08-27	2011-10-12	株式会社イギス	鼻炎治療剤
BR112012027765A2 (pt)	2010-04-30	2019-09-24	Enobia Pharma Inc	métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
EP2658979B1 (en) *	2010-12-27	2018-02-14	Alexion Pharmaceuticals, Inc.	Compositions comprising natriuretic peptides and methods of use thereof
EP2678002A2 (en)	2011-02-25	2014-01-01	Medtronic, Inc.	Therapy for kidney disease and/or heart failure
EP2741762A4 (en) *	2011-07-27	2015-04-15		NATRIURETIC PEPTIDE COMPOSITIONS AND PREPARATION METHODS
EP2750697A4 (en)	2011-09-02	2015-03-25	Medtronic Inc	CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
SG11201401605QA (en)	2011-10-19	2014-09-26	Alexion Pharma Holding	Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EP2794646A4 (en) *	2011-12-23	2015-12-09	Mayo Foundation	ASSESSMENT OF STRUCTURAL CHANGES AND RESULTS OF THE KIDNEYS
EP2853273A4 (en) *	2012-04-25	2016-01-13	Daiichi Sankyo Co Ltd	PROMOTER FOR BONE REPAIR
US10052366B2 (en)	2012-05-21	2018-08-21	Alexion Pharmaceuticsl, Inc.	Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2014063102A1 (en) *	2012-10-19	2014-04-24	Cornell University	Biomimetic boundary lubricants for articular cartilage
JP6232630B2 (ja) *	2013-03-10	2017-11-22	国立大学法人名古屋大学	骨系統疾患治療薬及びその用途
CN103159847B (zh) *	2013-04-12	2014-05-28	叶亮	一种利钠肽及其基因与用途
AU2015206515B2 (en)	2014-01-15	2019-12-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Cartilage targeting agents and their use
WO2016007873A1 (en)	2014-07-11	2016-01-14	The Regents Of The University Of Michigan	Compositions and methods for treating craniosynostosis
KR20170095278A (ko)	2014-12-05	2017-08-22	알렉시온 파마슈티칼스, 인코포레이티드	재조합 알칼리성 포스파타제를 이용한 발작 치료
JP2018502868A (ja) *	2015-01-09	2018-02-01	アセンディスファーマグロースディスオーダーズエー／エス	Ｃｎｐプロドラッグ
CA2973883A1 (en)	2015-01-28	2016-08-04	Alexion Pharmaceuticals, Inc.	Methods of treating a subject with an alkaline phosphatase deficiency
TWI773649B (zh)	2015-07-30	2022-08-11	美商拜奧馬林製藥公司	Ｃ型利尿納肽變異體治療骨骼發育不良之用途
EP3689897A1 (en) *	2015-07-31	2020-08-05	Igisu Co., Ltd.	A cnp cyclic peptide and a medicament, external preparation and cosmetic containing the cyclic peptide
MX2018002121A (es)	2015-08-17	2018-06-18	Alexion Pharma Inc	Elaboracion de fosfatasas alcalinas.
US11229686B2 (en)	2015-09-28	2022-01-25	Alexion Pharmaceuticals, Inc.	Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
EP3368062A4 (en)	2015-10-30	2019-07-03	Alexion Pharmaceuticals, Inc.	METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
PT3386531T (pt) *	2015-12-08	2021-12-29	Biomarin Pharm Inc	Uso de variantes do péptido natriurético tipo c para tratar a osteoartrite
CA3007987C (en) *	2016-01-08	2023-08-29	Ascendis Pharma Growth Disorders A/S	Controlled-release cnp agonists with low npr-c binding
ES2934582T3 (es) *	2016-01-08	2023-02-23	Ascendis Pharma Growth Disorders As	Profármacos de CNP con unión de portador en el resto del anillo
CA3008015A1 (en) *	2016-01-08	2017-07-13	Ascendis Pharma Growth Disorders A/S	Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
WO2017118707A1 (en)	2016-01-08	2017-07-13	Ascendis Pharma Growth Disorders A/S	Controlled-release cnp agonists with reduced side-effects
AU2017205693B2 (en) *	2016-01-08	2022-03-31	Ascendis Pharma Growth Disorders A/S	Controlled-release CNP agonists with low initial NPR-B activity
US10835578B2 (en) *	2016-01-08	2020-11-17	Ascendis Pharma Growth Disorders A/S	CNP prodrugs with large carrier moieties
US11065306B2 (en)	2016-03-08	2021-07-20	Alexion Pharmaceuticals, Inc.	Methods for treating hypophosphatasia in children
WO2017173395A1 (en)	2016-04-01	2017-10-05	Alexion Pharmaceuticals, Inc.	Methods for treating hypophosphatasia in adolescents and adults
JP7613826B2 (ja)	2016-04-01	2025-01-15	アレクシオンファーマシューティカルズ，インコーポレイテッド	アルカリホスファターゼによって筋力低下を治療すること
US10988744B2 (en)	2016-06-06	2021-04-27	Alexion Pharmaceuticals, Inc.	Method of producing alkaline phosphatase
EP3484523A1 (en) *	2016-07-13	2019-05-22	Ascendis Pharma A/S	Conjugation method for carrier-linked prodrugs
US11116821B2 (en)	2016-08-18	2021-09-14	Alexion Pharmaceuticals, Inc.	Methods for treating tracheobronchomalacia
PT3518930T (pt) *	2016-09-29	2023-04-28	Ascendis Pharma Growth Disorders As	Terapia de combinação com agonistas de cnp de libertação controlada
US20180194824A1 (en) *	2016-12-14	2018-07-12	University Of Iowa Research Foundation	Musclin peptides and methods of use thereof
US20200030414A1 (en) *	2017-01-24	2020-01-30	Daiichi Sankyo Company, Limited	Therapeutic agent for short stature
BR112019017103A2 (pt)	2017-03-10	2020-04-14	Quiapeg Pharmaceuticals Ab	conjugados liberáveis
CN110719786A (zh)	2017-03-31	2020-01-21	阿雷克森制药公司	用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法
WO2019190752A1 (en)	2018-03-30	2019-10-03	Alexion Pharmaceuticals, Inc.	Manufacturing of glycoproteins
EP3553082A1 (en)	2018-04-12	2019-10-16	Bayer Aktiengesellschaft	Brain natriuretic peptide engrafted antibodies
EP3553081A1 (en)	2018-04-12	2019-10-16	Bayer Aktiengesellschaft	Atrial natriuretic peptide engrafted antibodies
EP3553079A1 (en)	2018-04-12	2019-10-16	Bayer Aktiengesellschaft	C-type natriuretic peptide engrafted antibodies
EP3833377B1 (en)	2018-08-10	2023-11-22	Alexion Pharmaceuticals, Inc.	Bone healing at implants using alkaline phosphatase
EP3849660A1 (en)	2018-09-12	2021-07-21	QuiaPEG Pharmaceuticals AB	Releasable glp-1 conjugates
AU2020223441B2 (en)	2019-02-11	2025-05-22	Ascendis Pharma Growth Disorders A/S	Dry pharmaceutical formulations of CNP conjugates
EP3983437A1 (en)	2019-06-12	2022-04-20	Novartis AG	Natriuretic peptide receptor 1 antibodies and methods of use
US20220280647A1 (en) *	2019-08-12	2022-09-08	Biomarin Pharmaceutical Inc.	Hydrophobic Peptide Salts for Extended Release Compositions
TW202124422A (zh)	2019-09-16	2021-07-01	美商拜奧馬林製藥公司	Cnp變異體及其共軛物
KR20230024352A (ko) *	2020-06-12	2023-02-20	파마인 코포레이션	C형 나트륨이뇨 펩타이드 및 이의 급성 폐 손상의 치료에서의 방법
WO2022115563A1 (en) *	2020-11-25	2022-06-02	Prolynx Llc	Extended release hydrogel conjugates of c-natriuretic peptides
AU2022218782A1 (en)	2021-02-12	2023-08-17	Alexion Pharmaceuticals, Inc.	Alkaline phosphatase polypeptides and methods of use thereof
RU2763661C2 (ru) *	2021-03-31	2021-12-30	Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России)	Способ терапии и профилактики прогрессирования хронической почечной недостаточности
CA3226388A1 (en)	2021-07-09	2023-01-12	Biomarin Pharmaceutical Inc.	C-type natriuretic peptide variants to treat skeletal dysplasia in children
KR20240120731A (ko) *	2021-12-07	2024-08-07	바이오마린 파머수티컬 인크.	뼈 관련 장애의 c형 나트륨이뇨 펩타이드 요법
AU2022413318A1 (en)	2021-12-13	2024-05-16	Ascendis Pharma Growth Disorders A/S	Effective doses of cnp conjugates
EP4452300A1 (en) *	2021-12-20	2024-10-30	Institut National de la Santé et de la Recherche Médicale (INSERM)	Use of analog of c-type natriuretic peptide for the treatment of fgfr-related bone repair and bone formation impairment
KR20250005570A (ko) *	2022-03-11	2025-01-09	에이버맥스 바이오파마 인크.	치료제를 발현하기 위한 조성물 및 방법
EP4529454A1 (en)	2022-05-23	2025-04-02	Ascendis Pharma Growth Disorders A/S	Liquid pharmaceutical formulations of cnp compounds
WO2024094747A1 (en)	2022-11-02	2024-05-10	Novo Nordisk A/S	Cnp compounds
WO2024104922A1 (en)	2022-11-14	2024-05-23	Ascendis Pharma Growth Disorders A/S	Method of improving skeletal muscle function
CN120303284A (zh) *	2022-12-12	2025-07-11	株式会社Lg生活健康	皮肤改善用化妆料组合物
WO2024194300A1 (en)	2023-03-20	2024-09-26	Ascendis Pharma Growth Disorders A/S	Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
TW202513806A (zh)	2023-06-07	2025-04-01	美商拜奧馬林製藥公司	高通量篩選與身材矮小相關之基因變異體
WO2025054172A1 (en) *	2023-09-05	2025-03-13	E-Star Biotech, LLC	Formulations of manp and uses thereof
WO2025101863A1 (en)	2023-11-08	2025-05-15	Biomarin Pharmaceutical Inc.	Cnp variants, conjugates and formulations thereof
CN119529033A (zh) *	2024-12-02	2025-02-28	中山大学	一种用于npr-b靶向的超长效多肽及其在骨骼系统病症中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE121102T1 (de)	1990-04-20	1995-04-15	Hisayuki Matsuo	Neue im schwein vorkommende physiologisch aktive peptide.
JP2930380B2 (ja)	1990-07-13	1999-08-03	壽之松尾	ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
JP3026351B2 (ja)	1990-07-13	2000-03-27	壽之松尾	ブタｃｎｐ遺伝子及び前駆体蛋白
JP3026354B2 (ja)	1990-09-27	2000-03-27	壽之松尾	ヒトｃｎｐ遺伝子及び前駆体蛋白
US5252714A (en)	1990-11-28	1993-10-12	The University Of Alabama In Huntsville	Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja)	1991-01-31	1998-10-08	壽之松尾	Ｃｎｐ類似体ペプチド
AU6360394A (en)	1993-03-03	1994-09-26	Mayo Foundation For Medical Education And Research	Vasonatrin peptide and analogs thereof
US5846932A (en)	1993-11-12	1998-12-08	Genentech, Inc.	Receptor specific atrial natriuretic peptides
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
WO1997038983A1 (en)	1996-04-12	1997-10-23	Warner-Lambert Company	Irreversible inhibitors of tyrosine kinases
US6329375B1 (en)	1997-08-05	2001-12-11	Sugen, Inc.	Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US6136040A (en)	1998-03-05	2000-10-24	Washington University	Animal model with disrupted FGF-9 gene
IL125958A0 (en) *	1998-08-27	1999-04-11	Yeda Res & Dev	Animal model for fibroblast growth factor receptor associated chondrodysplasia
WO2000061631A1 (en)	1999-04-12	2000-10-19	Astrazeneca Ab	Modified pentapeptide antagonists of the atrial natriuretic peptide clearance receptor
US6849714B1 (en) *	1999-05-17	2005-02-01	Conjuchem, Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6407211B1 (en) *	1999-12-17	2002-06-18	Mayo Foundation For Medical Education And Research	Chimeric natriuretic peptides
ES2320101T3 (es)	2000-10-16	2009-05-19	Chugai Seiyaku Kabushiki Kaisha	Eritropoyetina conjugada con mono-peg.
JP2002178279A (ja)	2000-12-12	2002-06-25	Ulvac Japan Ltd	基板搬送方法
IL142118A0 (en) *	2001-03-20	2002-03-10	Prochon Biotech Ltd	Method and composition for treatment of skeletal dysplasias
US6858580B2 (en) *	2001-06-04	2005-02-22	Nobex Corporation	Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
BRPI0203172B8 (pt)	2001-09-28	2021-05-25	Nakao Kazuwa	composição farmacêutica para acondroplasia
WO2003079979A2 (en) *	2002-03-18	2003-10-02	Scios Inc.	Method for treating congestive heart failure
US6861236B2 (en) *	2002-05-24	2005-03-01	Applied Nanosystems B.V.	Export and modification of (poly)peptides in the lantibiotic way
AU2003285200A1 (en) *	2002-11-09	2004-06-03	Nobex Corporation	Modified carbamate-containing prodrugs and methods of synthesizing same
US7648962B2 (en) *	2002-11-26	2010-01-19	Biocon Limited	Natriuretic compounds, conjugates, and uses thereof
PL377813A1 (pl)	2002-11-26	2006-02-20	Biocon Limited	Modyfikowane związki natriuretyczne, ich koniugaty oraz zastosowania
US7772188B2 (en) *	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
EP1644740B1 (en) *	2003-06-17	2010-12-01	Otago Innovation Limited	Assessment of skeletal growth using measurements of nt-cnp peptides
EP1525890A1 (en)	2003-10-02	2005-04-27	Complex Biosystems GmbH	Protein-Proteophore complexes
ES2741524T3 (es)	2004-03-23	2020-02-11	Ascendis Pharma Gmbh	Profármaco polimérico con un enlazador autoinmolador
ES2465141T3 (es) *	2004-03-31	2014-06-05	Kazuwa Nakao	Remedio o medicamento preventivo para la artritis
EP1743653A4 (en) *	2004-03-31	2009-09-30	Kazuwa Nakao	COMPOSITION FOR INCREASING BODY SIZE
JP2005292718A (ja)	2004-04-05	2005-10-20	Furukawa Electric Co Ltd:The	光導波路、光導波路モジュールおよび光導波路の作成方法
US7968085B2 (en)	2004-07-05	2011-06-28	Ascendis Pharma A/S	Hydrogel formulations
ATE496060T1 (de) *	2004-07-15	2011-02-15	Univ Queensland	Proteinartige verbindungen und anwendungen davon
GB2427360A (en)	2005-06-22	2006-12-27	Complex Biosystems Gmbh	Aliphatic prodrug linker
CA2689492A1 (en)	2007-06-06	2008-12-18	Boehringer Ingelheim International Gmbh	Natriuretic fusion proteins
ES2632953T3 (es) *	2007-07-20	2017-09-18	Mayo Foundation For Medical Education And Research	Polipéptidos natriuréticos
JP2010539022A (ja)	2007-09-11	2010-12-16	モンドバイオテックラボラトリーズアクチエンゲゼルシャフト	治療剤としての、ｃ型ナトリウム利尿ペプチド単独または神経ペプチドａｆとの組合せの使用
US8377884B2 (en) *	2007-11-21	2013-02-19	Biomarin Pharmaceutical Inc.	Variants of C-type natriuretic peptides
EP2234603A1 (en)	2007-12-19	2010-10-06	EKR Therapeutics, Inc.	Room temperature stable, lyophilized natriuretic peptide formulations
EP2596805B1 (en)	2008-02-01	2021-10-27	Ascendis Pharma A/S	Prodrug comprising a drug-linker conjugate
BRPI0904622A2 (pt) *	2008-05-23	2016-06-21	Asubio Pharma Co Ltd	peptídeo com ação de prolongar a meia-vida de um peptídeo de interesse no plasma
EP2334335A1 (en)	2008-09-19	2011-06-22	Nektar Therapeutics	Polymer conjugates of cd-np peptides
PT3175863T (pt)	2009-05-20	2022-01-20	Biomarin Pharm Inc	Variantes do péptido natriurético de tipo c
WO2011089216A1 (en)	2010-01-22	2011-07-28	Ascendis Pharma As	Dipeptide-based prodrug linkers for aliphatic amine-containing drugs

2010
- 2010-05-20 PT PT161922299T patent/PT3175863T/pt unknown
- 2010-05-20 ES ES10778389.6T patent/ES2608457T3/es active Active
- 2010-05-20 HU HUE10778389A patent/HUE032582T2/en unknown
- 2010-05-20 JP JP2012512035A patent/JP5718909B2/ja active Active
- 2010-05-20 HU HUE16192229A patent/HUE057174T2/hu unknown
- 2010-05-20 KR KR1020187004835A patent/KR102033680B1/ko active Active
- 2010-05-20 AR ARP100101761A patent/AR078044A1/es active IP Right Grant
- 2010-05-20 EP EP16192229.9A patent/EP3175863B1/en active Active
- 2010-05-20 ES ES16192229T patent/ES2904360T3/es active Active
- 2010-05-20 DK DK10778389.6T patent/DK2432489T3/en active
- 2010-05-20 KR KR1020197029927A patent/KR102225470B1/ko active Active
- 2010-05-20 DK DK16192229.9T patent/DK3175863T3/da active
- 2010-05-20 EP EP21211450.8A patent/EP4029512A1/en active Pending
- 2010-05-20 RU RU2011152007/10A patent/RU2573911C2/ru active
- 2010-05-20 KR KR1020117030424A patent/KR101831923B1/ko active Active
- 2010-05-20 EP EP25175852.0A patent/EP4591934A2/en active Pending
- 2010-05-20 EP EP25151367.7A patent/EP4523749A3/en active Pending
- 2010-05-20 PL PL10778389T patent/PL2432489T3/pl unknown
- 2010-05-20 HR HRP20161739TT patent/HRP20161739T1/hr unknown
- 2010-05-20 AU AU2010249802A patent/AU2010249802B2/en active Active
- 2010-05-20 PL PL16192229T patent/PL3175863T3/pl unknown
- 2010-05-20 KR KR1020237032637A patent/KR20230142644A/ko not_active Ceased
- 2010-05-20 KR KR1020217006359A patent/KR20210027537A/ko not_active Ceased
- 2010-05-20 PE PE2011001729A patent/PE20120792A1/es active IP Right Grant
- 2010-05-20 US US12/784,117 patent/US8198242B2/en active Active
- 2010-05-20 TW TW99116187A patent/TWI471137B/zh active
- 2010-05-20 CN CN201080023189.6A patent/CN102481330B/zh active Active
- 2010-05-20 BR BR122019026832-0A patent/BR122019026832B1/pt active IP Right Grant
- 2010-05-20 WO PCT/US2010/035586 patent/WO2010135541A2/en not_active Application Discontinuation
- 2010-05-20 BR BRPI1012783-6A patent/BRPI1012783B1/pt active IP Right Grant
- 2010-05-20 HR HRP20220057TT patent/HRP20220057T1/hr unknown
- 2010-05-20 PT PT107783896T patent/PT2432489T/pt unknown
- 2010-05-20 CA CA2758581A patent/CA2758581C/en active Active
- 2010-05-20 EP EP10778389.6A patent/EP2432489B1/en active Active
- 2010-05-20 MX MX2011012277A patent/MX2011012277A/es active IP Right Grant
2011
- 2011-09-21 IL IL215287A patent/IL215287A/en active IP Right Grant
- 2011-09-28 ZA ZA2011/07087A patent/ZA201107087B/en unknown
- 2011-09-30 CL CL2011002430A patent/CL2011002430A1/es unknown
2012
- 2012-05-08 US US13/466,672 patent/US8598121B2/en not_active Ceased
2015
- 2015-01-23 US US14/604,262 patent/USRE46707E1/en active Active
- 2015-03-17 US US14/660,488 patent/US20160256553A1/en not_active Abandoned
2016
- 2016-10-24 US US15/332,793 patent/US20170051033A1/en not_active Abandoned
2017
- 2017-07-11 US US15/646,822 patent/USRE48267E1/en active Active
2022
- 2022-01-19 FI FIC20220003C patent/FIC20220003I1/fi unknown
- 2022-01-20 HU HUS2200004C patent/HUS2200004I1/hu unknown
- 2022-01-24 LU LU00248C patent/LUC00248I2/fr unknown
- 2022-01-28 FR FR22C1004C patent/FR22C1004I2/fr active Active
- 2022-02-01 NO NO2022003C patent/NO2022003I1/no unknown

Also Published As

Publication number	Publication date
BRPI1012783B1 (pt)	2021-09-21
DK2432489T3 (en)	2017-01-16
KR20120034660A (ko)	2012-04-12
US20100297021A1 (en)	2010-11-25
CA2758581A1 (en)	2010-11-25
KR102033680B1 (ko)	2019-10-18
HUE057174T2 (hu)	2022-04-28
MX2011012277A (es)	2011-12-12
ZA201107087B (en)	2012-12-27
HRP20220057T1 (hr)	2022-04-15
BRPI1012783A2 (pt)	2018-01-16
HRP20161739T1 (hr)	2017-03-10
IL215287A0 (en)	2011-11-30
EP2432489A4 (en)	2013-04-03
TWI471137B (zh)	2015-02-01
TW201100092A (en)	2011-01-01
PT3175863T (pt)	2022-01-20
RU2573911C2 (ru)	2016-01-27
AU2010249802A1 (en)	2011-10-13
EP3175863A1 (en)	2017-06-07
USRE48267E1 (en)	2020-10-20
AU2010249802B2 (en)	2017-06-08
EP4591934A2 (en)	2025-07-30
EP2432489A2 (en)	2012-03-28
EP4523749A2 (en)	2025-03-19
HUE032582T2 (en)	2017-09-28
USRE46707E1 (en)	2018-02-13
KR102225470B1 (ko)	2021-03-10
PE20120792A1 (es)	2012-07-27
PT2432489T (pt)	2016-12-07
US8598121B2 (en)	2013-12-03
KR20230142644A (ko)	2023-10-11
AR078044A1 (es)	2011-10-12
WO2010135541A2 (en)	2010-11-25
EP4029512A1 (en)	2022-07-20
CL2011002430A1 (es)	2012-02-17
LUC00248I2 (fi)	2025-03-04
PL3175863T3 (pl)	2022-03-21
WO2010135541A3 (en)	2011-01-20
US8198242B2 (en)	2012-06-12
US20170051033A1 (en)	2017-02-23
RU2011152007A (ru)	2013-06-27
US20120316114A1 (en)	2012-12-13
KR20180021233A (ko)	2018-02-28
CN102481330B (zh)	2014-12-10
KR20190119179A (ko)	2019-10-21
EP2432489B1 (en)	2016-10-05
US20160256553A1 (en)	2016-09-08
NO2022003I1 (no)	2024-08-05
EP4523749A3 (en)	2025-05-07
CA2758581C (en)	2022-06-14
HK1168279A1 (zh)	2012-12-28
FR22C1004I1 (fr)	2022-03-11
JP5718909B2 (ja)	2015-05-13
KR101831923B1 (ko)	2018-02-26
IL215287A (en)	2015-04-30
EP3175863B1 (en)	2021-12-01
FR22C1004I2 (fr)	2023-01-13
JP2012527244A (ja)	2012-11-08
DK3175863T3 (da)	2022-02-07
ES2904360T3 (es)	2022-04-04
KR20210027537A (ko)	2021-03-10
ES2608457T3 (es)	2017-04-11
HUS2200004I1 (hu)	2022-05-28
BR122019026832B1 (pt)	2021-08-24
CN102481330A (zh)	2012-05-30
PL2432489T3 (pl)	2017-05-31

Publication	Publication Date	Title
FIC20220003I1 (fi)	2022-01-19	Vosoritidi
DK2414015T3 (da)	2021-12-06	Laryngoskopsystem
DK2411442T4 (da)	2021-12-06	Umættet polyesterresin
DE112010004215A5 (de)	2012-08-23	Hydrostataktor
DE112010002949A5 (de)	2012-09-06	Kupplungstastpunkte
EP2469625A4 (en)	2015-11-04	OMNIBUS BAR
EP2491340A4 (en)	2014-12-24	TELEMETRY PHOTOGRAPHIC APPARATUS
EP2445547A4 (en)	2012-12-12	CATHETERISM SYSTEM
EP2397521A4 (en)	2013-12-11	BENZOXAZINE RESIN COMPOSITION
EP2407456A4 (en)	2012-08-15	CARBAZOLE ESTER-OXIME PHOTOINITIATOR
EP2440486A4 (en)	2013-09-25	CABLE RETRACTION SYSTEM
EP2401340A4 (en)	2012-08-22	POLYMER MODIFIER AGENTS
EP2509489A4 (en)	2015-04-01	SPRINKLER FOR EARLY HEEL REMOVAL
DK2430035T3 (da)	2013-05-27	Uracylspipooxetannukleosider
EP2433940A4 (en)	2012-10-10	SPIROIMIDAZOLONE DERIVATIVE
BRPI1008827A2 (pt)	2016-02-23	deisobutenizador
BRPI1014968A2 (pt)	2016-12-13	subalargador
DE112010002728A5 (de)	2012-06-21	Turboinhalator
DE112010004249A5 (de)	2012-11-29	Spindelaktor
DE112009005323A5 (de)	2012-07-26	Hebelarmprüfmaschine
DE112009005462T8 (de)	2013-03-28	Lenkungsssteuervorrichtung
BR112012004964A2 (pt)	2016-04-05	girocóptero
UY3953Q (es)	2010-11-30	Epiladora
BRPI1008070A2 (pt)	2016-03-15	tricianoboratos
EP2402744A4 (en)	2015-05-13	CARBURATION DETECTION METHOD